Sun Pharma agree deal to distribute AstraZeneca type-2 diabetes drug in India
pharmafile | March 24, 2016 | News story | Sales and Marketing | AstraZeneca, India, Sun Pharma, diabetes, oxra, type 2, type-2
Sun Pharma has agreed a deal with AstraZeneca to promote and distribute their type-2 diabetes drug, dapagliflozin, in India.
Marketed by AstraZeneca as Forxiga, this deal will see this leading diabetes medicine in India, distributed under the brand name, Oxra, by Sun Pharma. Under the terms of the arrangement, both companies will promote, market and distribute dapagliflozin in India under the different brand names.
Following regulatory approval, Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name, Oxramet. AstraZeneca India is currently in the process of seeking similar approval.
Abhay Gandhi, CEO of the Indian business at Sun Pharma, says: “This agreement for dapagliflozin further strengthens our partnership with AstraZeneca India. The addition of this innovative type-2 diabetes treatment bolsters our diabetes portfolio. We believe the extended portfolio will further enhance our service capabilities to offer customers and patients innovative medicines at affordable prices.”
Sanjay Murdeshwar, MD at AstraZeneca India, comments: “Dapagliflozin represents a significant advancement in the treatment of type-2 diabetes and this agreement supports our strategy of working with a local partner to maximise the value from our innovative medicines in a key emerging market. It also ensures a greater number of patients will have access to this important treatment option.”
Sean Murray
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …
